Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Parkinson's Syndrome Clinical Trial

Official title:
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Status Terminated

Clinical Trial Summary

This is a phase 3, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of [123I]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01950455
Study type	Interventional
Source	Navidea Biopharmaceuticals
Contact
Status	Terminated
Phase	Phase 3
Start date	November 2013
Completion date	January 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03667456` - Evaluation of the Uses of a Digital-assisted Self-rehabilitation Device (TELE-PARK)	N/A
Completed	`NCT03638479` - Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders
Not yet recruiting	`NCT06370195` - Effect of Stellate Ganglion Block on Drooling in Parkinson's Syndrome	N/A
Withdrawn	`NCT01950468` - A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes	Phase 3